🇺🇸 FDA
Patent

US 10080739

Aryl imidazoles and their use as anti-cancer agents

granted A61KA61K31/4178A61K31/4184

Quick answer

US patent 10080739 (Aryl imidazoles and their use as anti-cancer agents) held by APTOSE BIOSCIENCES INC. expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
APTOSE BIOSCIENCES INC.
Grant date
Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/4178, A61K31/4184, A61K31/4188, A61K31/4745